Dejan Micic to Colitis, Ulcerative
This is a "connection" page, showing publications Dejan Micic has written about Colitis, Ulcerative.
Connection Strength
2.456
-
Revisiting the Risk of Hospital Readmission in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2024 Apr 03; 30(4):688-689.
Score: 0.599
-
Serum Cytomegalovirus Polymerase Chain Reaction Test Is a Valuable Negative Predictor of Infection in Acute Severe Ulcerative Colitis. Dig Dis Sci. 2023 03; 68(3):897-901.
Score: 0.530
-
Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2021 10 18; 27(10):1620-1625.
Score: 0.505
-
Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.
Score: 0.135
-
Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol. 2021 11; 19(11):2444-2446.e2.
Score: 0.118
-
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
Score: 0.116
-
Drug-Induced Colitis. Clin Gastroenterol Hepatol. 2021 09; 19(9):1759-1779.
Score: 0.114
-
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
Score: 0.098
-
Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. J Gastroenterol Hepatol. 2017 Jun; 32(6):1143-1151.
Score: 0.093
-
In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. J Crohns Colitis. 2014 Nov; 8(11):1539-47.
Score: 0.076
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.027
-
Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-a agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 04; 45(8):1043-1057.
Score: 0.023
-
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394.
Score: 0.022